Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Single-agent nivolumab showed durable responses, manageable safety, and promising survival in patients with advanced hepatocellular carcinoma in the phase 1–2 CheckMate 040 study. We aimed to investigate nivolumab monotherapy compared with sorafenib monotherapy in the first-line setting for patients...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The lancet oncology Ročník 23; číslo 1; s. 77 - 90
Hlavní autoři:	Yau, Thomas, Park, Joong-Won, Finn, Richard S, Cheng, Ann-Lii, Mathurin, Philippe, Edeline, Julien, Kudo, Masatoshi, Harding, James J, Merle, Philippe, Rosmorduc, Olivier, Wyrwicz, Lucjan, Schott, Eckart, Choo, Su Pin, Kelley, Robin Kate, Sieghart, Wolfgang, Assenat, Eric, Zaucha, Renata, Furuse, Junji, Abou-Alfa, Ghassan K, El-Khoueiry, Anthony B, Melero, Ignacio, Begic, Damir, Chen, Gong, Neely, Jaclyn, Wisniewski, Tami, Tschaika, Marina, Sangro, Bruno
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Elsevier Ltd 01.01.2022 Elsevier Limited Elsevier
Témata:	Adverse events Aged Antiangiogenic agents Apoptosis Aspartate aminotransferase Cancer Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - psychology Clinical medicine Clinical trials Drug dosages Female Hematology, Oncology, and Palliative Medicine Hepatitis Hepatitis C Hepatocellular carcinoma Humans Immunotherapy Inhibitor drugs Life Sciences Liver cancer Liver Neoplasms - drug therapy Liver Neoplasms - mortality Liver Neoplasms - psychology Male Middle Aged Monoclonal antibodies Nivolumab - adverse effects Nivolumab - therapeutic use Patients Protein-tyrosine kinase Safety Sorafenib - adverse effects Sorafenib - therapeutic use Survival Targeted cancer therapy Toxicity Transplants & implants Asia
ISSN:	1470-2045, 1474-5488, 1474-5488
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!